Neumora Therapeutics Inc — Quarterly Cash Flow (NASDAQ:NMRA) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics

Quarterly Annual

Total assets 316.97 M256.75 M223.82 M177.83 M191.05 M Total liabilities 29.91 M28.38 M40.95 M45.67 M87.18 M Total equity 287.06 M228.36 M182.88 M132.16 M103.87 M Total liabilities & shareholders' equities 316.97 M256.75 M223.82 M177.83 M191.05 M Total debt ——39.45 M39.56 M114.53 M Net debt ——-178.14 M-131.96 M-68 M

뉴스

Neumora Therapeutics: Downgrading After Navacaprant Development Setback (NASDAQ:NMRA)

Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript

뉴모라 테라퓨틱스 CFO 밀리건, 5,119달러 상당 주식 매도

Neumora Therapeutics CFO Milligan sells $5119 in shares

Neumora Therapeutics, Inc. (NMRA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Slideshow (NASDAQ:NMRA) 2026-02-12

Intel, Wells Fargo among market cap stock movers on Tuesday

Oracle, Palantir among market cap stock movers on Monday

BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio

노모라 주식, 리어링크 파트너스, "시장수익률 상회" 등급으로 투자 분석 시작

Leerink Partners initiates coverage on Neumora stock with Outperform rating

일라이릴리 인수 기대감에 뉴모라 테라퓨틱스 주가 급등

Mizuho reiterates Outperform rating on Neumora Therapeutics stock